WO2008009963A3 - Pyrimidine derivatives as modulators of parathyroid hormone receptors - Google Patents

Pyrimidine derivatives as modulators of parathyroid hormone receptors Download PDF

Info

Publication number
WO2008009963A3
WO2008009963A3 PCT/GB2007/002767 GB2007002767W WO2008009963A3 WO 2008009963 A3 WO2008009963 A3 WO 2008009963A3 GB 2007002767 W GB2007002767 W GB 2007002767W WO 2008009963 A3 WO2008009963 A3 WO 2008009963A3
Authority
WO
WIPO (PCT)
Prior art keywords
parathyroid hormone
pyrimidine derivatives
modulators
hormone receptors
pth
Prior art date
Application number
PCT/GB2007/002767
Other languages
French (fr)
Other versions
WO2008009963A2 (en
Inventor
Caroline Minli Rachel Low
Lain Mair Mcdonald
Michael John Pether
John Spencer
Patrizia Tisselli
Paul Trevor Wright
Original Assignee
Black James Foundation
Caroline Minli Rachel Low
Lain Mair Mcdonald
Michael John Pether
John Spencer
Patrizia Tisselli
Paul Trevor Wright
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black James Foundation, Caroline Minli Rachel Low, Lain Mair Mcdonald, Michael John Pether, John Spencer, Patrizia Tisselli, Paul Trevor Wright filed Critical Black James Foundation
Publication of WO2008009963A2 publication Critical patent/WO2008009963A2/en
Publication of WO2008009963A3 publication Critical patent/WO2008009963A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Abstract

The present invention is concerned with pyrimidine derivatives, their intermediates, uses thereof and processes for their production. In particular, the present invention relates to parathyroid hormone (PTH) and parathyroid hormone related protein (PTHrp) receptor ligands, (PTH-I or PTH/PTHrp receptor ligands). The invention also relates to methods of preparing such ligands and to compounds which are useful as intermediates in such methods.
PCT/GB2007/002767 2006-07-21 2007-07-20 Pyrimidine derivatives as modulators of parathyroid hormone receptors WO2008009963A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0614579.1A GB0614579D0 (en) 2006-07-21 2006-07-21 Pyrimidine derivatives
GB0614579.1 2006-07-21

Publications (2)

Publication Number Publication Date
WO2008009963A2 WO2008009963A2 (en) 2008-01-24
WO2008009963A3 true WO2008009963A3 (en) 2008-05-08

Family

ID=36998543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/002767 WO2008009963A2 (en) 2006-07-21 2007-07-20 Pyrimidine derivatives as modulators of parathyroid hormone receptors

Country Status (2)

Country Link
GB (1) GB0614579D0 (en)
WO (1) WO2008009963A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200904437A (en) 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
CA2723961C (en) 2008-05-21 2017-03-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
GB0815369D0 (en) * 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
CN103501612B (en) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 The compound that cell is bred in cancer caused by suppression EGF-R ELISA
MX364378B (en) 2011-08-30 2019-01-21 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof.
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN105916849B (en) 2014-01-16 2020-07-07 Fmc公司 Pyrimidinyloxybenzene derivatives as herbicides
MX2017000779A (en) * 2014-07-17 2017-07-27 Chdi Foundation Inc Methods and compositions for treating hiv-related disorders.
WO2016043260A1 (en) * 2014-09-19 2016-03-24 塩野義製薬株式会社 Cyclic guanidine or amidine compound
EP3265445B1 (en) 2015-03-06 2021-05-05 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
ES2838977T3 (en) 2015-03-06 2021-07-02 Pharmakea Inc Fluoridated lysyl oxidase type 2 inhibitors and their uses
WO2016149315A1 (en) 2015-03-18 2016-09-22 E. I. Du Pont De Nemours And Company Substituted pyrimidinyloxy pyridine derivatives as herbicides
TW202400564A (en) 2015-06-05 2024-01-01 美商艾佛艾姆希公司 Pyrimidinyloxy benzene derivatives as herbicides
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
LT3319959T (en) 2015-07-06 2021-12-27 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
EP3322293B1 (en) 2015-07-13 2021-05-19 FMC Corporation Aryloxypyrimidinyl ethers as herbicides
JP7079772B2 (en) 2016-09-07 2022-06-02 ファーマケア，インク． Crystal form and production method of lysyl oxidase-like 2 inhibitor
CA3036062A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Uses of a lysyl oxidase-like 2 inhibitor
SG11201906164RA (en) 2017-01-11 2019-08-27 Rodin Therapeutics Inc Bicyclic inhibitors of histone deacetylase
EP3619206B1 (en) 2017-05-02 2024-02-14 FMC Corporation Pyrimidinyloxy benzo-fused compounds as herbicides
TW201843148A (en) * 2017-05-08 2018-12-16 國立大學法人京都大學 Compound, light emitting material and organic light emitting element
JP7152471B2 (en) 2017-08-07 2022-10-12 ロダン・セラピューティクス，インコーポレーテッド Bicyclic inhibitor of histone deacetylase
US11304946B2 (en) 2017-11-21 2022-04-19 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists
WO2019101647A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as ahr inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099776A1 (en) * 2002-05-23 2003-12-04 Amgen Inc. Calcium receptor modulating arylalkylamines
WO2005075458A1 (en) * 2004-02-10 2005-08-18 Sanofi-Aventis Pyrimidine derivatives as orexin receptors antagonists
WO2006071538A2 (en) * 2004-12-13 2006-07-06 Neurogen Corporation Substituted biaryl analogues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099776A1 (en) * 2002-05-23 2003-12-04 Amgen Inc. Calcium receptor modulating arylalkylamines
WO2005075458A1 (en) * 2004-02-10 2005-08-18 Sanofi-Aventis Pyrimidine derivatives as orexin receptors antagonists
WO2006071538A2 (en) * 2004-12-13 2006-07-06 Neurogen Corporation Substituted biaryl analogues

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GHOSH D ET AL: "2,4-bis(aryloxy)pyrimidines as antimierobial agents.", JOURNAL OF MEDICINAL CHEMISTRY NOV 1968, vol. 11, no. 6, November 1968 (1968-11-01), pages 1237 - 1238, XP002470439, ISSN: 0022-2623 *
KIM D H ET AL: "Synthesis of pyrido[1,2 a]pyrimido[4,5 d]pyrimidin 5 ones. Cyclization reaction of 4 [(3 hydroxy 2 pyridyl)amino] 2 phenyl 5 pyrimidinecarboxylic acid with acetic anhydride", JOURNAL OF HETEROCYCLIC CHEMISTRY 1975, vol. 12, no. 3, 1975, pages 477 - 480, XP002470440, ISSN: 0022-152X *
SAKAI NORIO ET AL: "New approach to the practical synthesis of tri- or tetrasubstituted pyrimidine derivatives: a four-component coupling reaction from a functionalized silane, two types of aromatic nitriles, and acetals.", ORGANIC LETTERS 13 OCT 2005, vol. 7, no. 21, 13 October 2005 (2005-10-13), pages 4705 - 4708, XP002470438, ISSN: 1523-7060 *
TRANTOLO D J ET AL: "Inhibitors of Bacillus subtilis DNA Polymerase III. Influence of Modifications in the Pyrimidine Ring of Anilino- and (Benzylamino)pyrimidines", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 29, no. 5, 1986, pages 676 - 681, XP002269094, ISSN: 0022-2623 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors

Also Published As

Publication number Publication date
GB0614579D0 (en) 2006-08-30
WO2008009963A2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
WO2008009963A3 (en) Pyrimidine derivatives as modulators of parathyroid hormone receptors
TW200801013A (en) Substituted benzofused derivatives and their use as vanilloid receptor ligands
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2010070658A3 (en) Improved process for the preparation of endothelin receptor antagonists
WO2008009415A3 (en) 4-heteroaryl-substituted 1-aminocyclohexane-1- and cyclohexene-1-derivatives having effects on the opiod receptor system
WO2008027812A3 (en) Imidazopyridine and imidazopyrimidine derivatives
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
WO2006031556A3 (en) Amidine substituted aryl aniline compounds
WO2006028936A3 (en) Heteromultimeric molecules
WO2009114181A3 (en) Substituted heterocycle fused gamma-carbolines solid
WO2007127317A3 (en) Humanized c-kit antibody
WO2009067578A3 (en) New vitamin d receptor activators and methods of making
WO2008125342A3 (en) Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals
WO2006133104A3 (en) Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists
EP1992698A4 (en) METHOD FOR SYNTHESIS OF SUPPRESSOR tRNA, DNA CONSTRUCT, AND PRODUCTION OF PROTEIN HAVING NON-NATURAL AMINO ACID INTEGRATED THEREIN BY USING THE DNA CONSTRUCT
WO2008151170A3 (en) Process for the synthesis of ramelteon and its intermediates
WO2009090548A3 (en) 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
FR2910230B3 (en) METHODS OF BIOFERTILIZATION FOR IMPROVING THE STABILITY OF YIELDS OF LARGE AGRONOMIC CROPS.
WO2010102778A3 (en) Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators
WO2010023310A3 (en) The an3 protein complex and its use for plant growth promotion
WO2007132354A3 (en) Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof
WO2010009879A3 (en) Methods for producing paricalcitol
WO2011024192A3 (en) Novel polymorphs of raltegravir
WO2009053446A3 (en) Pregabalin intermediates and process for preparing them and pregabalin
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07766326

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07766326

Country of ref document: EP

Kind code of ref document: A2